200 related articles for article (PubMed ID: 30816596)
21. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
22. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
23. Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption.
Guo Q; Cao Z; Wu B; Chen F; Tickner J; Wang Z; Qiu H; Wang C; Chen K; Tan R; Gao Q; Xu J
J Cell Physiol; 2018 Jan; 234(1):789-801. PubMed ID: 30078210
[TBL] [Abstract][Full Text] [Related]
24. NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K.
Lange AW; Yutzey KE
Dev Biol; 2006 Apr; 292(2):407-17. PubMed ID: 16680826
[TBL] [Abstract][Full Text] [Related]
25. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
[TBL] [Abstract][Full Text] [Related]
26. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
27. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.
Matsumoto M; Kogawa M; Wada S; Takayanagi H; Tsujimoto M; Katayama S; Hisatake K; Nogi Y
J Biol Chem; 2004 Oct; 279(44):45969-79. PubMed ID: 15304486
[TBL] [Abstract][Full Text] [Related]
28. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of culture conditions for osteoclastogenesis in RAW264.7 cells.
Cheng Y; Liu H; Li J; Ma Y; Song C; Wang Y; Li P; Chen Y; Zhang Z
PLoS One; 2022; 17(11):e0277871. PubMed ID: 36395187
[TBL] [Abstract][Full Text] [Related]
30. C/ebpα controls osteoclast terminal differentiation, activation, function, and postnatal bone homeostasis through direct regulation of Nfatc1.
Chen W; Zhu G; Tang J; Zhou HD; Li YP
J Pathol; 2018 Mar; 244(3):271-282. PubMed ID: 29083488
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.
Miyazaki M; Fujikawa Y; Takita C; Tsumura H
Clin Rheumatol; 2007 Feb; 26(2):231-9. PubMed ID: 16586042
[TBL] [Abstract][Full Text] [Related]
32. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T
J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory Effect of Purpurogallin on Osteoclast Differentiation in Vitro through the Downregulation of c-Fos and NFATc1.
Kim K; Kim TH; Ihn HJ; Kim JE; Choi JY; Shin HI; Park EK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463002
[TBL] [Abstract][Full Text] [Related]
34. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
[TBL] [Abstract][Full Text] [Related]
35. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
36. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
37. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation.
Crotti TN; Flannery M; Walsh NC; Fleming JD; Goldring SR; McHugh KP
Gene; 2006 May; 372():92-102. PubMed ID: 16513293
[TBL] [Abstract][Full Text] [Related]
38. Isoproterenol Increases RANKL Expression in a ATF4/NFATc1-Dependent Manner in Mouse Osteoblastic Cells.
Baek K; Park HJ; Baek JH; Kim HR
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053621
[TBL] [Abstract][Full Text] [Related]
39. Knockout and Double Knockout of Cathepsin K and Mmp9 reveals a novel function of Cathepsin K as a regulator of osteoclast gene expression and bone homeostasis.
Zhu G; Chen W; Tang CY; McVicar A; Edwards D; Wang J; McConnell M; Yang S; Li Y; Chang Z; Li YP
Int J Biol Sci; 2022; 18(14):5522-5538. PubMed ID: 36147479
[TBL] [Abstract][Full Text] [Related]
40. C/EBPα regulates osteoclast lineage commitment.
Chen W; Zhu G; Hao L; Wu M; Ci H; Li YP
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7294-9. PubMed ID: 23580622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
